“Solid tumors are very diverse,” Zhu said. “Some tumor cells lose or hide the antigen a therapy is designed to find — what we ...

President Stephen Hoge said the company’s recently announced positive Phase III results for its investigational personalized cancer vaccine, intismeran, in adjuvant melanoma support a broader effort ...

Blocking a tumor antioxidant restored T cell activity and made some resistant cancers more responsive to immunotherapy in mice.

T-cell receptor, or TCR, therapy is a cancer treatment that genetically reprograms immune cells, called T cells, to hunt down ...

The U.S. Food and Drug Administration has granted permission for investigators at the University of Colorado Anschutz to ...

New research reveals a promising new target for treating cancer by harnessing a type of molecule previously thought to do ...

UCLA researchers developed ready-made cancer-fighting T cells from cord blood stem cells that can attack solid tumors through ...

A new phase 1 clinical trial has found that an emerging immunotherapy is promising for treating recurrent glioblastoma, a highly aggressive and fatal brain cancer. Chimeric antigen receptor T (CAR-T) ...

An international research team led by Dr. Lucia Torres Fernández from the working groups of Professor Dr. Julie George and ...

When a new type of immunotherapy called CAR T-cell therapy was approved by the US Food and Drug Administration in 2017, it gave patients who had exhausted other treatment options hope where there was ...